Journal article
Tumor ablation by gene-modified T cells in the absence of autoimmunity
LXJ Wang, JA Westwood, M Moeller, CPM Duong, WZ Wei, J Malaterre, JA Trapani, P Neeson, MJ Smyth, MH Kershaw, PK Darcy
Cancer Research | Published : 2010
Abstract
Adoptive immunotherapy involving genetic modification of T cells with antigen-specific, chimeric, single-chain receptors is a promising approach for the treatment of cancer. To determine whether gene-modified T cells could induce antitumor effects without associated autoimmune pathology, we assessed the ability of T cells expressing an anti-Her-2 chimeric receptor to eradicate tumor in Her-2 transgenic mice that express human Her-2 as a self-antigen in brain and mammary tissues. In adoptive transfer studies, we demonstrated significant improvement in the survival of mice bearing Her-2+ 24JK tumor following administration of anti-Her-2 T cells compared with control T cells. The incorporation ..
View full abstractGrants
Funding Acknowledgements
This work was funded by Project Grants from the National Health and Medical Research Council (NHMRC), Cancer Council of Victoria, Bob Parker Memorial Fund, and the Susan Komen Breast Cancer Foundation. M. H. Kershaw and P.K. Darcy were supported by an NHMRC Senior Research Fellowship and Career Development Award, respectively. M.J. Smyth and J.A. Trapani were supported by an NHMRC Australia Research Fellowship and Senior Principal Research Fellowship, respectively.